Four-paper publication roadmap, target-venue selection, co-author strategy, and an 18-month timeline that respects the WP7 file-before-publish discipline.
A four-paper publication sequence over 18 months, sequenced as: (1) AI-native discovery methodology paper → (2) KAT8 white-space perspective → (3) Retina-first program proof-of-concept (data-dependent) → (4) Three-phase architecture review. Each preprinted on bioRxiv first. Each filed after its corresponding WP7 provisional cluster is on file.
The KAT8 white-space perspective (Paper 2) is the highest-impact-per-effort entry — the kind of finding that lands in Nature Aging or Cell Stem Cell without requiring new experimental data, and that primes the field for Atlas Bio's eventual KAT8 program.
An AI agent constrained by citation-grade discipline, evidence-vs-hypothesis lane separation, and safety-as-first-class output discipline produces a navigable, scored, reproducible map of the partial reprogramming chemical inducer landscape — before any wet-lab capital is committed. Demonstrates the methodology on a real, hot biotech landscape and surfaces a headline finding (KAT8 gap) as proof-of-utility.
Stakes the methodology territory before competitors publish their AI-discovery stories (Insilico Medicine, NewLimit, Altos all have AI-platform narratives in progress). Defensible without wet-lab data — it's a computational platform paper. Releases the Evidence Map JSON + Candidate Compound Table as supplementary data, making the paper highly citable.
H4K16ac loss is one of the most consistently reported aging epigenetic marks. KAT8/MOF is the canonical H4K16 acetyltransferase. Despite this mechanistic centrality, no clean small-molecule KAT8 activator has been disclosed, and the existing KAT6 inhibitor franchise runs in the wrong direction for aging. The NAD+/SIRT6/H4K16 antagonism (NAD+ supplementation drives down H4K16ac) is unappreciated. The paper makes the case for the KAT8 activator program as the highest-conviction unaddressed lane in cellular rejuvenation.
Highest-impact-per-effort. A perspective paper does not require new experimental data — it requires synthesis of existing literature with novel framing. The KAT8 finding is genuinely novel framing (no biotech has publicly identified it). The paper primes the field for Atlas Bio's eventual KAT8 program AND positions the company as the thought leader on the axis. Caveat: file Cluster A provisional (WP7) before this paper goes to preprint.
Demonstrates the three-phase architecture (Vit C + α-KG priming, AAV-OSK retinal pulse, Tazemetostat cyclic maintenance) in a relevant in vivo or ex vivo model. Reports the full aging-clock endpoint suite (Horvath, GrimAge, DunedinPACE, retinal-specific clocks per WP5) plus functional vision endpoints.
The capstone. Atlas Bio's first wet-lab-validated reprogramming paper. Critically, the Cluster B provisional (3-phase architecture) MUST be on file before any disclosure related to this work. If Paper 3 is rushed and disclosure precedes filing, the program-defining IP is forfeited.
Reviews the partial-reprogramming field through the lens of the three-phase architecture (priming, pulse, maintenance) that Atlas Bio identified through RIA-01. Positions the architecture as the inevitable convergent pattern that the competitive field is moving toward. Cites Papers 1–3 as foundation; positions the company as the framework's originator.
Cements the IP narrative around the three-phase architecture once Cluster B provisional is filed and Paper 3 has either been published or is in advanced review. Invited review status (after Papers 1–3 land) is the cleanest path. Provides citation-rich language for investor and partnership conversations.
Authorship signals credibility. The composition matters more for the first paper (methodology) than the later ones; once the methodology is anchored, subsequent papers can be more Atlas-Bio-internal.
| Slot | Profile / candidate type | Why this person |
|---|---|---|
| First author | RIA-01 lead engineer / Atlas Bio scientific lead | Owns the methodology and the data; standard convention |
| Co-author (chromatin biology) | Senior epigenetics academic with H4K16ac / KAT8 background | Mechanistic credibility for Papers 1 and 2; reduces "AI-only" perception |
| Co-author (reprogramming biology) | Sebastiano (Stanford), Reik (Cambridge), or another senior reprogramming PI | Domain credibility; reduces "novice in the field" perception. Higher cost (revenue-share, advisory equity) |
| Co-author (AAV / delivery) | 4DMT scientific contact or independent AAV-engineering academic | Cross-references existing Atlas Bio 4DMT case study; delivery-layer credibility |
| Co-author (computational methodology) | Bioinformatics / AI-for-biology academic familiar with structured-output LLM workflows | Reviewer-facing defense for Paper 1's methodology |
| Senior / corresponding author | Hugh / Atlas Bio CEO position | Standard convention; signals organizational accountability |
Atlas Bio's MS Study (April 2026) established a pre-registration pattern: predictions locked, hashed, published before data collection. RIA-01 publication outputs should follow the same discipline.
| Element | Pre-registration commitment |
|---|---|
| Paper 1 (methodology) | RIA-01 prime directive + scoring axes published as a pre-registration artifact before the Evidence Map is generated. Locks the methodology so reviewers see the discipline. |
| Paper 2 (KAT8 perspective) | Pre-register the headline-finding claim + search methodology hash on bioRxiv supplementary. Demonstrates the gap is not a retrospective rationalization. |
| Paper 3 (proof-of-concept) | Pre-register the primary endpoint (functional vision composite), the secondary endpoints (clock panel), the analysis plan, and the success criteria before any wet-lab work begins. |
| Paper 4 (review) | Less applicable — review-format paper. Disclose intellectual conflicts (the company has IP positions) prominently in the disclosures section. |
2C83D42F22...8290645E (per project memory). The pattern is: predictions locked — hash published — data collected — results compared to pre-registered predictions. RIA-01's outputs are not predictions in the same sense, but the discipline of "lock the method before generating the output; publish the lock" is fully transferable.
| Artifact | Release plan |
|---|---|
| RIA-01 prime directive (md + html) | Release publicly with Paper 1. Already in agents/Reprogramming/. Trade-secret-vs-open call: open release is the differentiator; the value is in the system, not the prompt. |
| WP1 Evidence Map (JSON) | Release as supplementary data with Paper 1. Citable artifact. |
| Candidate Compound Table (TSV/CSV) | Release as supplementary data with Paper 1 + Paper 2. |
| WP1.4 Competitor Pipeline Map | Release as supplementary data with Paper 2 (the perspective relies on this map). |
| WP4 Safety Risk Matrix | Release with Paper 3 once the safety endpoints are reported. |
| WP5 Endpoint Suite specification | Pre-register before Paper 3 wet-lab work begins; release fully with Paper 3. |
| WP7 Patent Landscape document | Internal only. Patent strategy is not for public release. |
| WP8 (this document) | Internal only. |
| Risk | Likelihood | Mitigation |
|---|---|---|
| Disclosure before provisional filing → IP loss | MED (procedural) | Strict file-before-publish discipline; counsel-managed gating |
| Competitor publishes KAT8 finding first | MED | Preprint Paper 2 early in the timeline; the perspective format requires only literature synthesis |
| Reviewer rejection on novelty grounds (chemical-cocktail literature already exists) | MED | Frame as methodology + landscape paper, not chemistry-novelty paper; the novelty is the AI agent + the gap finding |
| Paper 1 reviewers ask for wet-lab validation | HIGH | Pre-empt in discussion section; cite this as the explicit boundary of computational work; commit to Paper 3 follow-up |
| Paper 3 wet-lab data is null or weak | UNK | Pre-registration discipline ensures null results are still publishable; consider a "partial reprogramming combination did not enhance OSK in (model)" framing if needed |
| Tazemetostat use claims published before Cluster C provisional | HIGH if not managed | Counsel sign-off required before any paper mentioning Tazemetostat-in-reprogramming goes to preprint |
| Aging-clock endpoint findings cited for off-label / consumer wellness use | MED | Strong disclaimer language in every paper; refuse media engagement around consumer applications |